Avalo Therapeutics (AVTX) Assets Average (2015 - 2026)
Avalo Therapeutics' (AVTX) quarterly Assets Average came in at $108.2 million in Q1 2026, down 25.21% YoY from $144.6 million in Q1 2025, and down 10.44% on a QoQ basis from $120.8 million in Q4 2025.
Avalo Therapeutics (AVTX) Assets Average (2015 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 12 years of Assets Average data on file, last reported at $108.2 million in Q1 2026.
- Quarterly Assets Average fell 25.21% year-over-year to $108.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.2 million (down 25.21% YoY) and the FY2025 annual result came in at $133.6 million, up 55.59% from the prior year.
- Assets Average fell to $108.2 million in Q1 2026, from $120.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $144.6 million in Q1 2025 to a low of $25.1 million in Q4 2023.
- A 5-year average of $79.6 million and a median of $72.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average slumped 60.18% — and 2024, when it soared 395.77%.
- Tracing AVTX's Assets Average over 5 years: stood at $35.0 million in 2022, then decreased by 28.11% to $25.1 million in 2023, then jumped by 395.77% to $124.6 million in 2024, then fell by 3.06% to $120.8 million in 2025, then declined by 10.44% to $108.2 million in 2026.
- The last three Assets Average figures came in at $108.2 million (Q1 2026), $120.8 million (Q4 2025), and $125.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 295.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 295.33 Mn |
| Mar 31, 2026 | 108.17 Mn |
| Dec 31, 2025 | 120.78 Mn |
| Sep 30, 2025 | 125.84 Mn |
| Jun 30, 2025 | 132.55 Mn |
| Mar 31, 2025 | 144.63 Mn |
| Dec 31, 2024 | 124.59 Mn |
| Sep 30, 2024 | 103.38 Mn |
| Jun 30, 2024 | 116.02 Mn |
| Mar 31, 2024 | 72.36 Mn |
| Dec 31, 2023 | 25.13 Mn |
| Sep 30, 2023 | 26.75 Mn |
| Jun 30, 2023 | 30.24 Mn |
| Mar 31, 2023 | 34.80 Mn |
| Dec 31, 2022 | 34.96 Mn |
| Sep 30, 2022 | 34.39 Mn |
| Jun 30, 2022 | 47.06 Mn |
| Mar 31, 2022 | 71.06 Mn |
| Dec 31, 2021 | 87.79 Mn |
| Sep 30, 2021 | 79.72 Mn |